Novira Therapeutics Raises $23M for HBV and HIV Treatments
August 27, 2012
Novira Therapeutics has raised $23 million in Series A financing from a group of investors to continue developing antiviral drugs for the treatment of hepatitis B and HIV infections. 5AM Ventures and Canaan Partners led the round, while new investor WuXi PharmaTech and several existing investors also chipped in. As part of the deal, Scott Rocklage, a managing partner with 5AM Ventures, and Tim Shannon, a venture partner at Canaan Partners, have joined the Radnor, PA-based drug-discovery company.